• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Hong Kong·Healthcare·8158.HK
Share

China Regenerative Medicine International Limited Stocks

HK$ 0.24Last Updated 17.11.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

HK$ 9.31M

HK$ 0.24
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

China Regenerative Medicine International Limited operates as an investment holding entity, focusing on the development and distribution of a diverse portfolio of healthcare products and associated services. The company provides extensive health management solutions, covering health condition assessments, detoxification programs, fostering internal bodily balance, nourishing vital organs, and enhancing the immune system. Additionally, its beauty offerings encompass non-surgical medical aesthetics, essential dermatological care, anti-aging skin remedies, hair revitalization, skin firming treatments, localized body contouring, and intimate restoration services. Established in 1995, the organization was previously known as China Bio-Med Regeneration Technology Limited until its rebranding to China Regenerative Medicine International Limited in March 2015. Its headquarters are situated in Tsim Sha Tsui, Hong Kong.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

20.11.2026 13:46

Not Waiting for the Bottom: Burry Bought More of Tencent, BYD, and Adobe Shares as Their Prices Fell

20.11.2026 13:23

The short seller who highlighted Nvidia's problems has set his sights on a new target: Cerebras shares

20.11.2026 12:57

Stress Test: Which Nvidia Suppliers Will Be Hit Hardest After Huang's Departure?

20.11.2026 11:48

Anthropic's IPO Triggered a Sell-Off of Chipmakers' Stocks in Asia. What Should Investors Do?

20.11.2026 11:20

Top Stories This Morning: Anthropic's Debut, a Sale in Asia, Another IPO Cancellation, and Apple's AI Agent

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026